LIVN241018C45000
- 4.65
- 0.000.00%
LivaNova Newsroom
LivaNova Appoints Susan Podlogar as a New Director
LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts
Goldman Sachs Initiates LivaNova(LIVN.US) With Buy Rating, Announces Target Price $65
Analysts Conflicted on These Healthcare Names: LivaNova (LIVN), Johnson & Johnson (JNJ) and Avidity Biosciences (RNA)
Press Release: LivaNova to Announce Third-Quarter 2024 Results
LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital
Baird Upgrades LivaNova(LIVN.US) to Buy Rating, Raises Target Price to $66
LivaNova: Strong Buy Rating on Robust Revenue and Earnings Growth Outlook
Insider Sale: Director Francesco Bianchi Sells 1,500 Shares of LivaNova PLC (LIVN)
LivaNova Announces CHRO Hebbelinck's Planned Departure and Benefits
Barclays Maintains LivaNova(LIVN.US) With Hold Rating, Maintains Target Price $61
LivaNova (LIVN) Gets a Hold From Barclays
LivaNova PLC (NASDAQ:LIVN) Shares Could Be 36% Below Their Intrinsic Value Estimate
LivaNova Rises Following Possible CMS Reimbursement Boost for Vagus Nerve Stimulation
Baird Maintains LivaNova(LIVN.US) With Hold Rating, Maintains Target Price $55
LivaNova Hold Rating Justified by US VNS Reimbursement Uncertainty and Italian Legal Challenges
Returns At LivaNova (NASDAQ:LIVN) Are On The Way Up
LivaNova to Present at the Baird Global Healthcare Conference
Transcatheter Heart Valve Replacement Market Report 2024-2032 Featuring Edwards Lifescience, Abbott Laboratories, Medtronic, LIVANOVA, Boston Scientific, Artivion, MicroPort Scientific, Venus Medtech
Microelectronic Medical Implants Market Report 2024-2029, With Profiles of Leading Players, Including Abbott, Biotronik, Cochlear, LivaNova, Medtronic, Neuropace and Nevro